This company listing is no longer active
9CX Stock Overview
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney functions.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Cell MedX Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.093 |
| 52 Week High | US$0.17 |
| 52 Week Low | US$0.093 |
| Beta | 0.74 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -46.45% |
| 3 Year Change | -80.82% |
| 5 Year Change | -59.52% |
| Change since IPO | -81.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9CX | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.0% | -0.4% |
| 1Y | -46.4% | -2.8% | 3.4% |
Return vs Industry: 9CX underperformed the German Medical Equipment industry which returned -27.3% over the past year.
Return vs Market: 9CX underperformed the German Market which returned -17.8% over the past year.
Price Volatility
| 9CX volatility | |
|---|---|
| 9CX Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 9CX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 9CX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Dwayne Yaretz | cellmedx.com |
Cell MedX Corp., a biotech company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014.
Cell MedX Corp. Fundamentals Summary
| 9CX fundamental statistics | |
|---|---|
| Market cap | €6.62m |
| Earnings (TTM) | -€886.53k |
| Revenue (TTM) | €2.37k |
3,467x
P/S Ratio-7.5x
P/E RatioIs 9CX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9CX income statement (TTM) | |
|---|---|
| Revenue | US$2.34k |
| Cost of Revenue | US$43.24k |
| Gross Profit | -US$40.90k |
| Other Expenses | US$835.21k |
| Earnings | -US$876.11k |
Last Reported Earnings
Feb 28, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | -1,747.91% |
| Net Profit Margin | -37,440.51% |
| Debt/Equity Ratio | -28.3% |
How did 9CX perform over the long term?
See historical performance and comparison